ArticleScientific reports2025
Event-triggered smart dual hormone artificial pancreas for patient-specific drug delivery.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a chronic disorder that disrupts the body's ability to regulate blood glucose (BG) levels, leading to dangerous fluctuations such as hypoglycemia and hyperglycemia. In managing Type 1 Diabetes (T1D), the Dual Hormone Artificial Pancreas (DHAP) has emerged as a promising solution for maintaining optimal BG levels by administering both insulin and glucagon. However, the major challenges in DHAPs are slow dynamics in glucose sensing and delayed insulin absorption. In this paper, a Smart Dual Hormone Artificial Pancreas (SDHAP) with Event-triggered Feed-Back (FB)-Feed Forward (FF) control schemes are proposed to control the BG level of diabetic individuals and reject external disturbance due to food intake or exercise. Firstly, the classification of blood glucose level was performed with features extracted from the T1DiabetesGranada dataset using Machine Learning (ML) algorithms like K-Nearest Neighbor (KNN) and Support Vector Machine (SVM), and BG levels were predicted using time-series analysis. Secondly, the Event -Triggered Proportional-Integral feedback controllers: Proportional Integral (PI) and Model Predictive Control are designed based on the Bergman Minimal Model (BMM) model to deliver appropriate hormones namely insulin/glucagon based on predicted results. Finally, the FF controller was designed to reject external disturbances under hypoglycemia and hyperglycemia conditions. The results show the proposed SDHAP is more effective in controlling blood glucose by delivering patient-specific drugs with appropriate dosages based on individualized pathological conditions of T1D patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.